Polish medtech startup ONGENO secures €3.5M investment to complete stem cell therapy trial for multiple sclerosis treatment

ONGENO has a therapy, which has been proven in the first phase of the experiment to lead to improved sclerosis patient health, reduced disability, and lack of disease progression in the long term.